Notably, CAR1 (CD8 TMD‐CD3ζ SD)‐NK cells showed the best performance in anti‐tumour activity, particularly at effector‐to‐target (E:T) ratios of 0.2:1, 0.4:1 and 0.8:1 (CAR1‐NK vs. other six CAR‐NK, p < 0.001) (Figure 2D–G, Supporting Information S1: Table S2). This evidence concerns the gene CD8A and neoplasm.